SEC Form 4 · accession 0001209191-17-006855
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William R Ringo
Director
Period of report
Feb 1, 2017
Accepted (ET)
Feb 1, 2017 · 6:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2017 | M | 500 | $11.65 | A | 500 | D | |
| Common Stock | Feb 1, 2017 | S | 500 | $46.17 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $11.65 | Feb 1, 2017 | M | 500 | D | — | Sep 30, 2024 | Common Stock | 500 | 21,500 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016.
- F2The shares underlying this option vest at a rate of one-third per year on each anniversary of October 1, 2014.